Looks an interesting article… but to read in full one would need to subscribe.
‘Although the recently published treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica suggest minimising the use of glucocorticoids,1 these drugs are still the standard treatment for these diseases. In The Lancet Rheumatology, Alain Saraux and colleagues' Article on the BACHELOR trial,2 a randomised, double-blind, placebo-controlled study, reports impressive results on the use of baricitinib, a Janus kinase (JAK) inhibitor, to treat recent-onset polymyalgia rheumatica without the use of oral glucocorticoids.’